GIMDx, Inc. and IncellDx, Inc. Announce OEM and International Distribution Agreement for Single Cell Immuno-Oncology and Oncology Diagnostic Products in China

CARLSBAD, Calif., Oct. 19, 2017 /PRNewswire/ -- GIMDx, Inc. (hereinafter referred to as "GIMDx") announced today that it has concluded an exclusive OEM and International Distribution agreement for IncellDx, Inc. (hereinafter referred to as "IncellDx") single cell immune-oncology and oncology diagnostic products in China. GIMDx will supply its parent company, Guangzhou Improve Medical Instruments Co., Ltd. (hereinafter referred to as "Improve Medical"), with IncellDx component products which will be kitted and co-labeled for the Chinese IVD market. Products included in the agreement are IncellDx's proprietary single cell quantification of Programmed Death Ligand 1 (PD-L1) on tumor cells and immune cell subtypes, single cell HPV E6/E7 mRNA detection for cervical cytology, and the IncellPREP® tissue single cell suspension system for solid tumors. Improve Medical will be the first company in China to offer the quantitative PD-L1 assay with cell cycle using flow cytometric or circulating tumor cell (CTC) technology.

Dr. Larry Liu, President and CEO of GIMDx stated his enthusiasm for this agreement by saying: "IncellDx is a company we have been looking forward to collaborating with for quite some time. This agreement is the starting point for our journey into the Chinese healthcare market in the field of advanced clinical diagnostics."

Dr. Guanhua Deng, Chairman and CEO of Improve Medical said: "IncellDx is leading the global frontier with cutting-edge diagnostics like PD-L1. This collaboration is an excellent fit with Improve's philosophy of serving the Chinese healthcare market with innovative and dedicated disease diagnostics."

Dr. Bruce Patterson, CEO and founder of IncellDx, elaborates by saying, "Our 3Dx technology used in all of our immune-oncology and oncology products powerfully combines multiplex RNA in situ hybridization/quantification, multiplex protein quantification, and DNA cell cycle simultaneously in individual cells. This assay platform yields unparalleled amounts of information on every cell in a heterogeneous tumor environment to better serve the needs of the healthcare market. This assay platform can be used on flow cytometers, fluorescence microscopes, and CTC machines commonly used in diagnostic laboratories."

About GIMDx, Inc.

GIMDx, Inc. located in Carlsbad, California, USA , is a subsidiary of Improve Medical Instruments Co., Ltd., Guangzhou, China. GIMDx specializes in commercial collaborations and R&D laboratory support for IVD companies with particular emphasis on addressing China's unique market needs by leveraging our parent company's established commercial channels in leading Chinese hospitals, as well as other partners in the Chinese healthcare market.

About Guangzhou Improve Medical Instruments Co., Ltd.

Guangzhou Improve Medical Instruments Co., Ltd., established in 1996, is a high-tech enterprise which provides relevant technologies, products and services for Clinical Laboratory and Clinical Nursing.  In 2009, Improve Medical became a listed company on the Growth Enterprise Board on the Shenzhen Stock Exchange. Improve Medical has become the leading enterprise in the Chinese domestic high-end healthcare market and one of the main suppliers for Evacuated Blood Collection System in the world. 

About IncellDx, Inc.

IncellDx, Inc., located at Menlo Park, California, USA is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA in situ hybridization, and DNA cell cycle analysis. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.

SOURCE GIMDx, Inc.